In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ivax International GmbH

Latest From Ivax International GmbH

Deals Shaping The Medical Industry, November 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Hopes For Disease Modification In Huntington’s Disease

A group at the Lawrence Berkeley National Laboratory believes that a synthetic antioxidant previously shown to reduce apoptosis and enhance cell survival in vitro can ameliorate the symptoms of Huntington’s Disease – and beyond its neuroprotective effects, may even have disease modifying properties. They’ve published the first proof of concept in animals, aiming to bring the compound into human studies.

BioPharmaceutical Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals